Evidence used
- CISA confirms exploitation in the wild.
- Exploitation requires an existing local or physical foothold with privileges.
- EPSS is 2.95% for the current model date.
BlackTreeCVE IntelligenceMicrosoft · Enhanced Cryptographic Provider
CISA confirms exploitation in the wild and lists 2021-11-17 as the remediation due date.
CISA confirms exploitation in the wild and lists 2021-11-17 as the remediation due date.
Patch availableMicrosoft Enhanced Cryptographic Provider contains an unspecified vulnerability that allows for privilege escalation.
Microsoft Enhanced Cryptographic Provider contains an unspecified vulnerability that allows for privilege escalation.
The current structured CVE record identifies a security weakness, but the root cause requires confirmation in the linked vendor material.
An attacker operating through local access may attempt exploitation with low privileges. If successful, the issue may gain additional privileges.
Microsoft Enhanced Cryptographic Provider contains an unspecified vulnerability that allows for privilege escalation.
The current structured CVE record identifies a security weakness, but the root cause requires confirmation in the linked vendor material.
An attacker operating through local access may attempt exploitation with low privileges. If successful, the issue may gain additional privileges.
CVSS severity, EPSS forecast probability, public exploit material and CISA-confirmed exploitation are separate signals.
CISA added this CVE to its Known Exploited Vulnerabilities catalogue on 2021-11-03.
No exploit-tagged reference or CISA SSVC proof-of-concept state is currently recorded. Research may still exist outside the structured feeds.
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N/E:F/RL:O/RC:CCommon Vulnerability Scoring System 3.1: the compact vector below is decoded into plain language.
Operational remediation based on structured source evidence.
Published 8 Jun 2021 · Last source change 21 Oct 2025, 23:25 UTC · CWE not yet assigned
Missing structured fields: CWE classification. Missing data is not evidence of low risk; review the primary advisory.